Celgene Corp. (CELG)

• Annual Data
• Quarterly Data

Celgene Corp., Consolidated Statement of Cash Flows (quarterly data)

USD $ in millions

	3 months ended	Sep 30, 2018		Jun 30, 2018		Mar 31, 2018		Dec 31, 2017		Sep 30, 2017		Jun 30, 2017		Mar 31, 2017		Dec 31, 2016		Sep 30, 2016		Jun 30, 2016		Mar 31, 2016		Dec 31, 2015		Sep 30, 2015		Jun 30, 2015		Mar 31, 2015		Dec 31, 2014		Sep 30, 2014		Jun 30, 2014		Mar 31, 2014		Dec 31, 2013		Sep 30, 2013		Jun 30, 2013		Mar 31, 2013
	Net income (loss)
	Depreciation
	Amortization
	Impairment charges
	Provision for accounts receivable allowances
	Deferred income taxes
	Change in value of contingent consideration and success payments
	Gain on sale of business
	Net loss on sales of debt securities available-for-sale
	Fair value adjustments on equity investments
	Share-based compensation expense
	Share-based employee benefit plan expense
	Derivative instruments
	Realized losses on marketable securities available for sale
	Other, net
	Accounts receivable
	Inventory
	Other operating assets
	Accounts payable and other operating liabilities
	Income tax payable
	Payment of contingent consideration
	Deferred revenue
	Change in current assets and liabilities, excluding the effect of acquisitions and disposals
	Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
	Net cash provided by (used in) operating activities
	Proceeds from sales of debt securities available-for-sale
	Purchases of debt securities available-for-sale
	Capital expenditures
	Proceeds from sales of equity investment securities
	Purchases of equity investment securities
	Payments for acquisition of businesses, net of cash acquired
	Other
	Net cash (used in) provided by investing activities
	Payment for treasury shares
	Proceeds from short-term borrowing
	Principal repayments on short-term borrowing
	Proceeds from issuance of long-term debt
	Principal repayments on current portion of long-term debt
	Net proceeds (payments) from common equity put options
	Payment of contingent consideration
	Net proceeds from share-based compensation arrangements
	Excess tax benefit from share-based compensation arrangements
	Net cash provided by (used in) financing activities
	Effect of currency rate changes on cash and cash equivalents
	Net increase (decrease) in cash and cash equivalents

Based on: 10-Q (filing date: 2018-10-25), 10-Q (filing date: 2018-07-26), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-07), 10-Q (filing date: 2017-10-26), 10-Q (filing date: 2017-07-27), 10-Q (filing date: 2017-04-27), 10-K (filing date: 2017-02-10), 10-Q (filing date: 2016-10-27), 10-Q (filing date: 2016-07-28), 10-Q (filing date: 2016-05-03), 10-K (filing date: 2016-02-11), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-07-28), 10-Q (filing date: 2015-04-30), 10-K (filing date: 2015-02-20), 10-Q (filing date: 2014-10-28), 10-Q (filing date: 2014-07-29), 10-Q (filing date: 2014-04-29), 10-K (filing date: 2014-02-13), 10-Q (filing date: 2013-10-29), 10-Q (filing date: 2013-07-30), 10-Q (filing date: 2013-04-30).